What is Thera technologies?
Thera Technologies is a specialty biopharmaceutical company focused on developing and commercializing innovative therapies. Its primary areas of focus include prescription products for individuals living with HIV, as well as advancing research in specialized therapies for oncology and rare or niche patient populations. The company emphasizes a patient-centered approach, aiming to address unmet medical needs through dedicated research and development.
How much funding has Thera technologies raised?
Thera technologies has raised a total of $95M across 2 funding rounds:
Debt
$40M
Debt
$55M
Debt (2022): $40M with participation from Marathon Asset Management
Debt (2024): $55M led by TD Bank Group and Investissement Quebec
Key Investors in Thera technologies
TD Bank Group
TD Bank Group, a prominent financial institution, offers a comprehensive suite of financial products and services. Its wholesale banking segment provides capital markets and corporate investment banking services, including underwriting and strategic advisory, making it a key player in facilitating enterprise-level financing.
Investissement Quebec
Investissement Quebec is a provincial financial institution dedicated to fostering investment and economic development within Quebec. It provides businesses with a range of financial solutions, including loans and equity investments, supporting companies with strategic growth initiatives.
Marathon Asset Management
Marathon Asset Management Lp is an investment management firm that holds a significant stake in MCAP Global Finance (UK) LLP. Its involvement suggests a strategic financial backing, potentially focused on debt financing instruments that support corporate expansion and operational scaling.
What's next for Thera technologies?
The recent major strategic investment suggests Thera Technologies is poised for significant scaling and potentially the advancement of its pipeline candidates into later-stage clinical trials or commercialization. The company's focus on HIV, oncology, and niche patient populations indicates a targeted strategy to capture market share in areas with substantial unmet needs. Future capital raises or strategic partnerships may be anticipated as the company progresses its therapeutic offerings, leveraging its established track record of securing substantial financing.
See full Thera technologies company page
